For 26-year-old Austin Tattersall, leaving his Victorian home is a meticulous ritual. Each exit involves ensuring he carries an essential item—a pair of EpiPen devices, crucial for managing his severe food allergies, also known as anaphylaxis. The EpiPen, an autoinjector that delivers life-saving adrenaline, is a constant companion, often stashed in his girlfriend’s handbag or a backpack.
“They’ve never really changed since I was a child,” Tattersall shared, referring to his allergies to eggs, nuts, and dairy. Despite his vigilance, he considers himself fortunate for not having used the EpiPen recently. His caution stems from a lifetime of careful food management, a skill honed since childhood when his parents would cook his meals separately to avoid cross-contamination.
Living with Anaphylaxis: A Daily Challenge
Now responsible for his own meals, Tattersall meticulously checks food labels and prefers dining at familiar restaurants. “I’ve looked at the menu before I go or even call up the restaurant to say I am coming in and ask if they would be able to cater for me,” he explained. His lifestyle, heavily influenced by his studies in sports science and nutrition, revolves around understanding and controlling his diet.
“Everyone’s so understanding, which is amazing,” he said, acknowledging the support from family and friends who are educated about his condition. This understanding is vital, as anaphylaxis can be triggered by seemingly innocuous exposures.
Innovative Treatments: A New Hope
Recently, a new treatment option has emerged for anaphylaxis sufferers in Australia—neffy, an adrenaline-based nasal spray. Unlike traditional autoinjectors, neffy is smaller and doesn’t require an injection, offering a less invasive alternative. Available in pharmacies with a private prescription, neffy represents a significant advancement in allergy management.
“Australia continues to have one of the highest rates of allergy problems in the developed world,” said Professor Mimi Tang, an immunologist at the Murdoch Children’s Research Institute.
Despite the rising rates of allergies, the exact cause remains elusive. However, the introduction of neffy could provide a new layer of security for those at risk. Maria Said AM from Allergy & Anaphylaxis Australia highlighted the importance of having multiple treatment options, emphasizing the need for quick recognition and response to allergic reactions.
Cost and Accessibility: Weighing the Options
While neffy is not yet listed on the Pharmaceutical Benefits Scheme (PBS), a submission is pending review in March 2026. Until then, the cost of neffy remains a consideration for many, with prices around $97 per spray on a private prescription. In contrast, EpiPen devices, which are PBS-listed, offer a more cost-effective option at approximately $25 with a prescription.
“It’s good that there’s something else on the market,” Tattersall remarked, expressing interest in the new treatment but also comfort in the familiarity of his EpiPens.
Dr. Nick Coatsworth, speaking on the Today show, noted the potential popularity of neffy among children, citing its effectiveness and ease of use. However, he stressed the importance of education in using any adrenaline-based medication.
Looking Ahead: The Future of Allergy Management
As the landscape of allergy treatment evolves, the introduction of neffy marks a promising development. For individuals like Tattersall, the choice of treatment becomes a personal decision, balancing comfort, convenience, and cost. The ongoing advancements in allergy management underscore the critical need for education and awareness in effectively handling severe allergic reactions.
With the pending PBS listing and ongoing discussions among healthcare professionals, the future of anaphylaxis treatment in Australia appears poised for significant change. As new therapies emerge, the focus remains on empowering individuals with the tools and knowledge to manage their conditions safely and effectively.
